Friedel David
Department of Gastroenterology, NYU-Langone-Long Island, Mineola, NY, USA.
Transl Gastroenterol Hepatol. 2023 Jun 15;8:30. doi: 10.21037/tgh-23-12. eCollection 2023.
This narrative review discusses Barrett's esophagus management in the context of perceived deficiencies or controversies. Barrett's adenocarcinoma incidence has not clearly been impacted by Barrett's screening and surveillance.
The following report was derived from articles using PubMed and Google searches. The search was concentrated on Barrett's esophagus screening and management guidelines.
Comprehensive literature searches that highlight potential deficiencies or controversies regarding the current approach to Barrett's esophagus were employed. Esophageal adenocarcinoma incidence is rapidly increasing and this malignancy usually presents in an advanced and unresectable state. This is despite the significant expenditure of resources and time in endoscopic screening for and surveillance of Barrett's esophagus. Thus, more widespread screening for Barrett's esophagus may be considered. In addition, there are apparent inefficiencies and precision lack in the performance of endoscopic surveillance. This relates mainly to the lack of endoscopic cues for dysplasia. On the other hand, relatively low-risk subjects have frequent screening or surveillance procedures increasing cost. Lastly, endoscopic ablation for Barrett's with dysplasia has moderately good efficacy, especially for eradication of dysplasia, but mandates intensive post-therapy endoscopic surveillance. There is some concern for subsurface development of advanced Barrett's lesions. Fortunately, there is intense research in improving Barrett's esophagus diagnosis and treatment. Our narrative review will delineate deficiencies and potential measures to remedy them.
In conclusion, screening for Barrett's esophagus and surveillance in Barrett's subjects have minimal established benefits, but proposed changes in screening practices and innovations in Barrett's esophagus endoscopic surveillance and dysplasia therapy have great promise.
本叙述性综述在认识到的不足或争议背景下讨论巴雷特食管的管理。巴雷特腺癌的发病率尚未因巴雷特食管的筛查和监测而受到明显影响。
以下报告源自使用PubMed和谷歌搜索的文章。搜索集中在巴雷特食管的筛查和管理指南。
采用全面的文献检索,突出当前巴雷特食管治疗方法中潜在的不足或争议。食管腺癌的发病率正在迅速上升,且这种恶性肿瘤通常在晚期且不可切除的状态下出现。尽管在内镜筛查和监测巴雷特食管方面投入了大量资源和时间,但情况依然如此。因此,可以考虑更广泛地筛查巴雷特食管。此外,内镜监测的执行明显存在效率低下和缺乏精准性的问题。这主要与发育异常缺乏内镜提示有关。另一方面,相对低风险的受试者频繁进行筛查或监测程序增加了成本。最后,对发育异常的巴雷特食管进行内镜消融有较好的疗效,尤其是对于发育异常的根除,但需要强化治疗后的内镜监测。对于巴雷特高级别病变的黏膜下发展存在一些担忧。幸运的是,在改善巴雷特食管的诊断和治疗方面有大量研究。我们的叙述性综述将阐述不足之处及补救的潜在措施。
总之,巴雷特食管的筛查和对巴雷特食管患者的监测已确立的益处极小,但提议的筛查实践改变以及巴雷特食管内镜监测和发育异常治疗方面的创新前景广阔。